trial
as of 2026-07-01MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics
NCTId NCT03376763
at a glance
Phase 4 · Completed
Enrollment 201 (actual)
Sponsored by Korea Otsuka Pharmaceutical Co., Ltd.
Primary completion 2021-11-19
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
201 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2017-11-21
Primary completion
2021-11-19
Eligibility
ALL · 19 Years · 64 Years
Interventions & indications
Sponsors
Korea Otsuka Pharmaceutical Co., Ltd.Lead Sponsor
Investigators
1
Jun Soo Kwon, MD, PhDPrincipal Investigator
Sites
27 total
Gongju, South KoreaGuri-si, South KoreaSeongnam-si, South KoreaSeongnam-si, South KoreaUijeongbu-si, South KoreaYongin-si, South KoreaJeju City, South KoreaJeonju, South KoreaChungju, South KoreaDaegu, South KoreaDaegu, South KoreaDaegu, South Korea
Facts & assertions
4 sourced
Enrollment
201
Phase
PHASE4
Primary Completion Date
2021-11-19
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator
person